Daiichi Sankyo

News

AstraZeneca and Daiichi Sankyo's Datroway comes good in the delayed TROPION-Breast02 trial as a frontline triple-negative breast cancer treatment.

News

AstraZeneca and Daiichi Sankyo are eyeing regulatory filings for Enhertu in early breast cancer after a second phase 3 trial delivers.

News

Highlights of the WCLC show include new data for AstraZeneca's Tagrisso, Summit's ivonescimab, MSD/Daiichi's I-DXd, and BMS/Systimmune's iza-bren.

News

AZ and Daiichi Sankyo have claimed FDA approval for Datroway in lung cancer after switching indications for the TROP2-directed drug.

News

AstraZeneca and Daiichi Sankyo have revealed the data they hope will move Enhertu into frontline therapy for HER2-positive advanced breast cancer.

News

MSD and Daiichi Sankyo suffer another setback with their HER3 programme ahead of a crucial data readout at ASCO.